Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lupin Buys Stake In South Africa’s Pharma Dynamics; Aims To Be In Top 3  

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - After months of negotiations, Indian generic drug maker Lupin acquired a 60 percent equity stake in South Africa's sixth largest generic drug maker Pharma Dynamics with the goal of joining the top ranks of companies in South Africa in three years

You may also be interested in...



India’s Lupin Set For Global Generics Growth; Logs 53 Percent Profit Jump In Q2

NEW DELHI - Indian drug maker Lupin said it was poised to grow further in the global generics market as it reported a 53 percent jump in consolidated quarterly net profit, driven by a strong across-the-board performance

India’s Lupin Set For Global Generics Growth; Logs 53 Percent Profit Jump In Q2

NEW DELHI - Indian drug maker Lupin said it was poised to grow further in the global generics market as it reported a 53 percent jump in consolidated quarterly net profit, driven by a strong across-the-board performance

Ranbaxy Disappointed By U.S. FDA’s Warning Letters And “Import Alert”

MUMBAI - India's largest drug maker Ranbaxy expressed its disappointment over U.S. FDA's move to issue warning letters and import alerts against drug products manufactured at its sites in Dewas in Madhya Pradesh and Paonta Sahib in Himachal Pradesh

UsernamePublicRestriction

Register

OM013195

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel